Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration.
To determine the efficiency of a single-dose and a multiple-dose protocol for GnRH antagonist administration. Randomized clinical trial. University hospital, tertiary medical center. Sixty-one patients undergoing controlled ovarian stimulation (COS) and IVF/ICSI. COS with either a multiple-dose (MD) or a single-dose (SD) protocol for GnRH antagonist (cetrorelix) administration, or with a long protocol (LP) for GnRH agonist (buserelin) administration, followed by oocyte retrieval, IVF/ICSI, and embryo transfer. Follicular development and serum levels of E2 and LH. The SD protocol for cetrorelix was associated with a more reduced level of follicular development, lower levels of serum estradiol on the day of HCG administration, and a more reduced number of zygotes than the LP for buserelin. The pregnancy and implantation rates did not differ significantly for the three study groups. The MD and SD GnRH antagonist protocols were effective for preventing LH surge and appear to elicit an equivalent pregnancy rate to that corresponding to a LP GnRH agonist. In terms of follicular development, the SD protocol requires further modification, including flexible scheduling or possibly a small reduction of the dosage of the administered cetrorelix.